Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • DRL receives FDA nod...

    DRL receives FDA nod for anti-psoriasis cream

    Written by Ruby Khatun Khatun Published On 2017-12-03T10:45:01+05:30  |  Updated On 3 Dec 2017 10:45 AM IST
    DRL receives FDA nod for anti-psoriasis cream

    Hyderabad: Dr. Reddy's Laboratories Ltd (DRL) said its US subsidiary Promius Pharma, LLC, received fifth consecutive and final approval for its specialty drug Impoyz (clobetasol propionate) cream, 0.025 percent, from the US Food and Drug Administration.


    A statement from the drug maker said it is a first-cycle NDA (new drug application) approval for the Proprietary Products Group, a substantial milestone in the pharmaceutical industry.


    Impoyz (clobetasol propionate) cream, 0.025 percent, is a high-potency topical steroid approved for the treatment of moderate to severe plaque psoriasis in patients 18 years of age or older.


    This approval is another example of the deep and broad capabilities of the Proprietary Products business unit at Dr. Reddy's. The organization has achieved several milestones within drug, device and formulation research and development for novel therapies, it said.


    Anil Namboodiripad, Senior Vice President, Proprietary Products and President Promius Pharma, said they are looking forward to working with their partner, Encore Dermatology, to commercialize.


    "The fifth consecutive first cycle NDA approval represents Dr. Reddy's long-term commitment to building an organization that delivers innovative medical solutions. We are looking forward to working with our partner, Encore Dermatology, to bring this novel treatment to providers and their patients," Namboodiripad said.


    "Encore is excited about adding another great product to our portfolio and looking forward to the opportunity to commercialize a new product for the treatment of mild to moderate psoriasis as well as broadening our portfolio outside of atopic dermatitis and acne," said Robert Moccia, CEO of Encore Dermatology Inc, said.


    The most common side effect of Impoyz cream includes discoloration of the treated site, the release said.


    Psoriasis is a serious medical condition affecting approximately 7.5 million people in the United States. Impoyz, formerly referred to as DFD-06, had been recently licensed to Encore Dermatology Inc for the commercialization of the product in the United States, it added.

    Anil Namboodiripadanti psoriasis creamapprovalClobetasol PropionateDFD-06Dr Reddy'sDr Reddy's LaboratoriesDr Reddy's LabsDr. Reddy’s laboratories LtdDRLFDAfirst-cycleFood and Drug AdministrationImpoyzPharmaceutical industryPromius PharmaPromius Pharma LLCPsoriasisreceivesspecialty drugUS subsidiary
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok